Licensing status

Publication and contact information


Monitoring microRNA-1202 (miR-1202) expression to predict antidepressant treatment response

Cell culture and patient sample studies suggest monitoring miR-1202 expression could help predict response to antidepressants in patients with depression. In human prefrontal cortex samples, miR-1202 levels were lower in patients with depression than healthy controls. In human neural progenitor cells, chronic treatment with the marketed antidepressants imipramine or Celexa citalopram increased miR-1202 levels compared with no treatment. In blood samples from patients with depression, miR-1202 expression was lower in remitter patients than nonresponders and controls, and miR-1202 levels were higher in patients after Celexa treatment than before treatment. Next steps could include testing correlations of miR-1202 with other antidepressants and in wider patient populations.
Imipramine is a generic tricyclic antidepressant.
Citalopram is a generic selective serotonin reuptake inhibitor and is marketed by H. Lundbeck A/S and Actavis plc as Celexa.

SciBX 7(27); doi:10.1038/scibx.2014.814
Published online July 17, 2014

Patent and licensing status unavailable

Lopez, J.P. et al. Nat. Med.;
published online June 8, 2014;
Contact: Gustavo Turecki, McGill University, Montreal, Quebec, Canada